Thrombolytic medicine synergist and its preparing process
A technology for thrombolytic drugs and synergists, applied in the field of biopharmaceuticals, can solve the problems of patent applications and literature reports that no synergists are found, and achieve the effects of improving thrombolytic effects, reducing usage, and reducing drug costs.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0038] (1) Cloning of human P11 protein gene and construction, screening and identification of prokaryotic expression plasmid
[0039] Strains and expression vectors: the expression strains Escherichia coli BL21, E.coli DH5α, and plasmid pBV220 are all preserved by the Institute of Basic Medical Sciences, Academy of Military Medical Sciences of the Chinese People's Liberation Army. They are all publicly available elsewhere.
[0040] Enzymes and biochemical reagents: restriction enzymes BamHI, EcoR I, Taq DNA polymerase and T 4 DNA ligase was purchased from TaKaRa Company; nucleic acid molecular weight standard DL2000 was purchased from TaKaRa Company; protein molecular weight standard was purchased from Jingke Bioengineering Company; DNA purification kit was from Boda Biotechnology Company; plasmid extraction kit was from Promega Company. The Bradford method protein quantification kit was purchased from Pleibo Company. Human thrombin, human plasminogen, human fibrinogen, and...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com